<DOC>
	<DOC>NCT00633932</DOC>
	<brief_summary>This study is to evaluate the efficacy of esomeprazole 20 mg once daily and 40 mg once daily for 8 weeks on healing of Reflux Esophagitis in patients with reflux esophagitis in comparison with omeprazole 20 mg once daily by assessment of presence/absence of Reflux Esophagitis at Week 8 according to the Los Angeles classification .</brief_summary>
	<brief_title>Reflux Esophagitis Phase III Study (Initial Treatment)</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Esophagitis, Peptic</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Endoscopically verified Reflux Esophagitis classified into Los Angeles classification Grade A, B, C or D within 1 week before randomisation Gastric or duodenal ulcer verified by EGD within 12 weeks before randomisation. Use of any PPI from 14 days before EGD performed at the screening visit to the day of randomisation.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Reflux Esophagitis</keyword>
</DOC>